{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T13:09:10Z","timestamp":1773234550407,"version":"3.50.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP18K15071"],"award-info":[{"award-number":["JP18K15071"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We monitored anti-drug antibodies and disease-specific biomarkers in three patients with a nonsense mutation from a Japanese Fabry family treated with enzyme replacement therapy (ERT). In two male patients from the family, neutralizing anti-drug antibodies were induced at an early stage of ERT, the antibody titer peak being found at an earlier stage of ERT in the patient treated with 1.0\u00a0mg\/kg agalsidase beta than in that treated with 0.2\u00a0mg\/kg agalsidase alfa. Then, the antibody titers decreased with continuation of ERT. The formation of neutralizing anti-drug antibodies adversely affected the plasma globotriaosylsphingosine (Lyso-Gb3) level and urinary globotriaosylceramide (Gb3) excretion in both patients, the impact being greater in the patient treated with 0.2\u00a0mg\/kg agalsidase alfa than in that treated with 1.0\u00a0mg\/kg agalsidase beta. The difference might be explained by the different doses of the infused enzymes based on supersaturation of the antibodies. In a heterozygous Fabry female from the family, no sign of antibody formation was found, and both the plasma Lyso-Gb3 level and urinary Gb3 excretion, which were moderately increased at the baseline, decreased gradually. No deterioration of the manifestations or laboratory findings was observed during ERT in either of the patients. Thus, monitoring of anti-drug antibodies and biomarkers in these Fabry patients provided us with important information on their pathological condition during ERT.<\/jats:p>","DOI":"10.1007\/s13730-022-00738-7","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T05:02:30Z","timestamp":1665118950000},"page":"171-175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Monitoring of anti-drug antibodies and disease-specific biomarkers in three patients from a Japanese Fabry family treated with enzyme replacement therapy"],"prefix":"10.1007","volume":"12","author":[{"given":"Takao","family":"Kubota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"738_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30.","journal-title":"Orphanet J Rare Dis"},{"key":"738_CR2","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.2147\/DDDT.S207856","volume":"13","author":"U Ramaswami","year":"2019","unstructured":"Ramaswami U, Beck M, Hughes D, Kampmann C, Botha J, Pintos-Morell G, West ML, Niu D-M, Nicholls K, Giugliani R, FOS Study Group. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry outcome survey (FOS) analysis. Drug Des Devel Ther. 2019;13:3705\u201315.","journal-title":"Drug Des Devel Ther"},{"key":"738_CR3","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","volume":"14","author":"A Ortiz","year":"2021","unstructured":"Ortiz A, Kanters S, Hamed A, DasMahapatra P, Poggio E, Maski M, Aguiar M, Ponce E, Jansen JP, Ayers D, Goldgrub R, Desnick R. Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis. Clin Kidney J. 2021;14:1136\u201346.","journal-title":"Clin Kidney J"},{"key":"738_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","volume":"35","author":"PB Deegan","year":"2012","unstructured":"Deegan PB. Fabry disease, enzyme replacement therapy and the significance of antibody responses. J Inherit Metab Dis. 2012;35:227\u201343.","journal-title":"J Inherit Metab Dis"},{"key":"738_CR5","first-page":"69","volume":"2","author":"Y Takase","year":"2018","unstructured":"Takase Y, Nagai T, Kubota T, Takeo H, Kosuga M, Okuyama T, Tabata H. Progression of left ventricular fibrosis in a woman with Anderson-Fabry disease: longitudinal observations using two-dimensional speckle-tracking echocardiography. CASE (Phila). 2018;2:69\u201372.","journal-title":"CASE (Phila)"},{"key":"738_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2020.100650","volume":"25","author":"T Tsukimura","year":"2020","unstructured":"Tsukimura T, Tayama Y, Shiga T, Hirai K, Togawa T, Sakuraba H. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy. Mol Genet Metab Rep. 2020;25: 100650.","journal-title":"Mol Genet Metab Rep"},{"key":"738_CR7","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","volume":"22","author":"H Sakuraba","year":"2018","unstructured":"Sakuraba H, Togawa T, Tsukimura T, Kato H. Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy. Clin Exp Nephrol. 2018;22:843\u20139.","journal-title":"Clin Exp Nephrol"},{"key":"738_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgmr.2021.100804","volume":"29","author":"T Shiga","year":"2021","unstructured":"Shiga T, Tsukimura T, Namai Y, Togawa T, Sakuraba H. Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease. Mol Genet Metab Rep. 2021;29: 100804.","journal-title":"Mol Genet Metab Rep"},{"key":"738_CR9","doi-asserted-by":"publisher","first-page":"8080","DOI":"10.3390\/ijms21218080","volume":"21","author":"I Simonetta","year":"2020","unstructured":"Simonetta I, Tuttolomondo A, Daidone M, Pinto A. Biomarkers in Anderson-Fabry disease. Int J Mol Sci. 2020;21:8080.","journal-title":"Int J Mol Sci"},{"key":"738_CR10","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1073\/pnas.0712309105","volume":"105","author":"JM Aerts","year":"2008","unstructured":"Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, Vedder AC, Rombach SM, Cox-Brinkman J, Somerharju P, Boot RG, Hollak CE, Brady RO, Poorthuis BJ. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"738_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","volume":"28","author":"PD Whitfield","year":"2005","unstructured":"Whitfield PD, Calvin J, Hoggs S, O\u2019Driscoll E, Halsall D, Burling K, Maguire G, Wright N, Cox TM, Meikle PJ, Deegan PB. Monitoring enzyme replacement therapy in Fabry disease \u2013 role of urine globotriaosylceramide. J Inherit Metab Dis. 2005;28:21\u201333.","journal-title":"J Inherit Metab Dis"},{"key":"738_CR12","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1159\/000488121","volume":"43","author":"MD del Pino","year":"2018","unstructured":"del Pino MD, Andr\u00e9s A, Bernab\u00e9u A\u00c1, de Juan-Rivera J, Fern\u00e1ndez E, de Garc\u00eda D\u00edaz JD, Hern\u00e1ndez D, Lu\u00f1o J, Fern\u00e1ndez IM, Paniagua J, de la Paz MP, Rodr\u00edguez-P\u00e9rez JC, Santamar\u00eda R, Torra R, Ambros JT, Vidau P, Torregrosa J-V. Fabry nephropathy: an evidence-based narrative review. Kidney Blood Press Res. 2018;43:406\u201321.","journal-title":"Kidney Blood Press Res"},{"key":"738_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1681\/ASN.2014121226","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Stypmann J, Duning T, Schmitz B, Brand S-M, Brand E. Serum-mediated inhibition of enzyme replacement therapy in Fabry disease. J Am Soc Nephrol. 2016;27:256\u201364.","journal-title":"J Am Soc Nephrol"},{"key":"738_CR14","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neu\u00dfer LP, Rudnicki M, Nordbeck P, Canaan-K\u00fchl S, Nowak A, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand S-M, Brand E. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2879\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"738_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JM, Poorthuis BJ, Groener J, Donker-Koopman W, Hendriks E, Mirzaian M, Kuiper S, Wijburg FA, Hollak CE, Linthorst GE. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS\u00a0One. 2012;7: e47805.","journal-title":"PLoS\u00a0One"},{"key":"738_CR16","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1681\/ASN.2018030329","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Brand E. Effects of enzyme replacement therapy and antidrug antibodies in patients with Fabry disease. J Am Soc Nephrol. 2018;29:2265\u201378.","journal-title":"J Am Soc Nephrol"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-022-00738-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-022-00738-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-022-00738-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T07:10:07Z","timestamp":1682925007000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-022-00738-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["738"],"URL":"https:\/\/doi.org\/10.1007\/s13730-022-00738-7","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]},"assertion":[{"value":"15 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors obtained informed consent from all individual participants in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}